TABLE 3.

Variables associated with definitive ceftriaxone therapy ^a

Variable, N (%)	Definitive ceftriaxone (N = 78)	Definitive AmpC stable (N = 146)	UnAdjOR (95% CI)	P-value	AdjOR (95% CI)	P-value
Post-intervention group	72 (92%)	37 (25%)	35.4 (14.2–88.0)	<0.001	34.7 (13.9–86.6)	<0.001
Intensive care unit admission	35 (45%)	82 (56%)	0.64 (0.4–1.1)	0.12	0.75 (0.37–1.5)	0.44
Stroke/Transient Ischemic Attack	16 (21%)	14 (10%)	2.4 (1.1–5.3)	0.02	Not tested	–
Peripheral vascular disease	26 (33%)	31 (21%)	1.9 (1.0–3.4)	0.048	Not tested	–
Charlson Score ≥5	51 (65%)	77 (53%)	1.7 (0.96–2.9)	0.068	Not tested	–
Bloodstream infection	30 (39%)	49 (34%)	1.24 (0.70–2.2)	0.47	Not tested	–
Infectious diseases consult	51 (65%)	113 (77%)	0.55 (0.30–1.0)	0.053	Not tested	–
COVID-19 infection	5 (6%)	21 (14%)	0.41 (0.15–1.1)	0.08	Not tested	–

^a Hosmer-Lemeshow test result (method used: backward, likelihood ratio), P = 0.999. COVID-19, coronavirus disease of 2019.